プロプラノロールは,統合失調症の治療の補助剤として使用されています
Lancet (London, England)
|September 17, 1977
まとめ
プロプラノロールは,慢性統合失調症の症状の管理に役立ちます. ある研究では,プロプラノロールを投与された患者は,主要な鎮静剤を長期にわたって投与した後でも,プラセボを受けた患者よりも大きな改善を示しました.
科学分野:
- 精神科医は精神病を患っている.
- 薬理学 薬理学とは
背景:
- 慢性統合失調症の症状は,主要な鎮静剤による治療にもかかわらず,しばしば持続します.
- 補助療法の探求は,患者のアウトカムを改善するために非常に重要です.
研究 の 目的:
- 慢性統合失調症の追加治療としてプロプラノロルの有効性を評価する.
- 従来の抗精神病薬に不十分な反応を示した患者の症状の寛解を評価する.
主な方法:
- 12週間のランダム化,プラセボ対照試験が行われました.
- 慢性統合失調症の14人の患者は,既存のクロロプロマジン療法に加えてプロプラノロールまたはプラセボを投与されました.
主要な成果:
- 両グループは12週間にわたって改善を示しました.
- プロプラノロール群は,プラセボ群と比較して,症状の改善が著しく増加した.
結論:
- プロプラノロルは,慢性統合失調症の持続的な症状を管理するための有用な補助療法としての可能性を実証しています.
- 治療抵抗性統合失調症のベータブロッカーのさらなる研究が必要である.
関連する概念動画
CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications


